The Therapeutic Goods Administration has rejected the application from GlaxoSmithKline to have Benlysta approved for use in Australia.
If you want to sign a petition to have this reconsidered, here is a link: http://www.thepetitionsite.com/271/988/810/demand-treatment-for-australian-lupus-patients/
There's two big issues here:
1. Benlysta might not help all lupus patients, but it could help some. For those people for whom this is the best possible treatment, it ought to be available.
2. New lupus treatments cost a great deal of money to develop. If the treatments can't then be used, there's not a lot of incentive for companies to continue to develop treatments (or perhaps ultimately a cure.)